Evidence map›Paper›PMID 29968978›Full record

ArticleInfection & chemotherapy2018

Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia.

Tark Kim, Heungsup Sung, Yong Pil Chong, Sung Han Kim, Eun Ju Choo, Sang Ho Choi, Tae Hyong Kim, Jun Hee Woo, Yang Soo Kim, Sang Oh Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection & chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Clinical course and prognostic factors ofFrontiers in cellular and infection microbiology · 2024
    Article
  3. Late-Onset GranulomatousInfection & chemotherapy · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Tark KimDepartment of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.ORCID https://orcid.org/0000-0002-8829-4183
Heungsup SungDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yong Pil ChongDepartment of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sung Han KimDepartment of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Eun Ju ChooDepartment of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Sang Ho ChoiDepartment of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Tae Hyong KimDepartment of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
Jun Hee WooDepartment of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yang Soo KimDepartment of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sang Oh LeeDepartment of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. soleemd@amc.seoul.kr.ORCID https://orcid.org/0000-0003-1381-8787
Ulsan College · KRSoonchunhyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTrimethoprim/sufamethoxazole (TMP/SMX) is the recommended treatment for Pneumocystis jirovecii pneumonia (PCP). However, the efficacy and the safety of alternative salvage treatments are less guarauteed especially when patient experiences treatment failure and/or an adverse drug reactions (ADR). The purpose of this study is to recognize potential risk factors imitating successful treatment with TMP/SMX among PCP patients. MATERIALS AND

methodsNinety one adult patients diagnosed with PCP were included after searching electronical medical records from January 2013 through July 2015 at Asan Medical Center Seoul, Korea. We compared clinical characteristics and laboratory findings including bronchoalveolar lavage (BAL) fluid analysis in patients who experienced TMP/SMX treatment failure or ADR (the case group) versus those who did not (the control group).

resultsAmong the enrolled PCP patients, 39 (42.9%) required salvage treatment owing to either treatment failure (28, 28.6%) and/or ADR (17, 18.7%). The BAL lymphocyte percentage (25% [IQR, 8-40%] vs. 47% [IQR, 15-62%]; P = 0.005) was lower in the case group. Diabetes mellitus (adjusted odds ratio [aOR] 4.98, 95% confidence interval [95% CI] 1.20-18.58), glomerular filtration rate ≤50 mL/min (aOR 4.48, 95% CI 1.08-18.66), and BAL lymphocyte percentage ≤45% (aOR 9.25, 95% CI 2.47-34.58) were independently associated with the case group in multivariate analysis.

conclusionThis study suggests that BAL lymphocyte count may play some role during PCP treatment. Further studies should be followed to reveal what the role of BAL lymphocyte is in the PCP treatment.

Indexed as

Adverse drug reactionPneumocystis jiroveciiPneumoniaTreatment failureTrimethoprim/sulfamethoxazole

Identifiers

PMID29968978
PMCPMC6031595
OpenAlexW2811023198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.